Iguratimod Report: Delta4 Hyper-C Case Study

Unveiling Drug Discoveries: Download Hyper-C Iguratimod Report

Dive into the groundbreaking exploration of iguratimod’s vast potential, meticulously unearthed by Delta4’s state-of-the-art Hyper-C platform. From constructing intricate molecular models to unveiling promising novel indications, our comprehensive report offers a treasure trove of insights.

Included in the report:

Download Hyper-C Iguratimod Report

Play Video about Iguratimod Case Study

About Delta4

Helping Millions Of Patients With Rare Diseases By Pioneering The Treatments Of Tomorrow, Today

Delta4, an AI-enabled drug repurposing leader, empowers healthcare professionals to discover and improve treatments. Our data-driven approach combines AI and expert insights for effective indication expansion. Drug repurposing, though complex, saves time and resources in treatment development. Our platform, Hyper-C, identifies and assesses potential drug candidates. We continuously enhance our platform and algorithms to uncover promising candidates efficiently. Our dedicated team ensures high-quality service for successful drug repurposing.

Download Delta4's Iguratimod Hyper-C Report

 Download the report and step into the future of drug indication expansion!

Our Partners & Clients

Proud Member of

Streamlining Transparency and Cooperation provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.